Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines.
作者信息
Issa Aurora Felice Castro
机构信息
Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil.
出版信息
Arq Bras Cardiol. 2024 Mar 4;120(12):e20230821. doi: 10.36660/abc.20230821. eCollection 2024.
Abstract
摘要
相似文献
1
Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines.蒽环类药物化疗患者评估中的生物标志物
Arq Bras Cardiol. 2024 Mar 4;120(12):e20230821. doi: 10.36660/abc.20230821. eCollection 2024.
2
Renin-Angiotensin System Inhibition and Beta Blockade Adrenergic May Be Useful to Attenuate Cardiotoxicity by Anthracyclines.肾素-血管紧张素系统抑制和β受体阻滞剂可能有助于减轻蒽环类药物的心脏毒性。
Arq Bras Cardiol. 2023 May;120(5):e20230280. doi: 10.36660/abc.20230280.
3
New advances in medical imaging technology for the evaluation of anthracycline-induced cardiotoxicity.用于评估蒽环类药物所致心脏毒性的医学成像技术的新进展。
Chin Med J (Engl). 2022 Aug 5;135(15):1883-1885. doi: 10.1097/CM9.0000000000002123.
4
Acute cardiotoxicity of anthracyclines: Revisiting an old concept in the modern era of oncohaematology.蒽环类药物的急性心脏毒性：在现代肿瘤血液学时代重新审视一个旧概念。
Arch Cardiovasc Dis. 2024 Apr;117(4):297-300. doi: 10.1016/j.acvd.2024.02.003. Epub 2024 Mar 5.
5
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.评论：蒽环类药物治疗的癌症患儿的心脏毒性：关于右丙亚胺的立场声明。
Pediatr Blood Cancer. 2023 Oct;70(10):e30604. doi: 10.1002/pbc.30604. Epub 2023 Jul 28.
6
Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea.钠-葡萄糖共转运蛋白 2 抑制剂可改善接受含蒽环类化疗的 2 型糖尿病患者的临床结局：来自韩国全国队列数据的模拟目标试验。
Sci Rep. 2023 Dec 8;13(1):21756. doi: 10.1038/s41598-023-48678-1.
7
Anthracyclines: biosynthesis, engineering and clinical applications.蒽环类抗生素：生物合成、工程改造及临床应用
Nat Prod Rep. 2022 Apr 20;39(4):814-841. doi: 10.1039/d1np00059d.
8
Expanding the scope of aromatic polyketides by combinatorial biosynthesis.通过组合生物合成扩展芳香族聚酮化合物的范围。
Comb Chem High Throughput Screen. 2003 Sep;6(6):501-12. doi: 10.2174/138620703106298680.
9
Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.比索洛尔与安慰剂在接受蒽环类药物治疗的患者中的比较（CONTROL 试验）：原理和研究设计。
J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491.
10
Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.阿帕替尼单药治疗与吉西他滨为基础的化疗治疗蒽环类药物化疗失败后的晚期软组织肉瘤患者的疗效。
J Cancer Res Clin Oncol. 2024 Jan 31;150(2):58. doi: 10.1007/s00432-023-05575-4.
本文引用的文献
1
New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy.接受多柔比星为基础的化疗的乳腺癌患者中的新心血管生物标志物。
Arq Bras Cardiol. 2023 Dec;120(12):e20230167. doi: 10.36660/abc.20230167.
2
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy - a prospective analysis.接受蒽环类化疗患者的心脏和非心脏生物标志物——一项前瞻性分析。
Cardiooncology. 2023 Apr 27;9(1):23. doi: 10.1186/s40959-023-00174-1.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment.促炎循环标志物：评估乳腺癌治疗中无症状急性心血管毒性的新指标。
J Chemother. 2021 Apr;33(2):106-115. doi: 10.1080/1120009X.2021.1873632. Epub 2021 Jan 22.
5
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.血清生物标志物在接受心脏毒性癌症治疗的癌症患者中的作用：心力衰竭协会的心脏肿瘤学研究小组和欧洲心脏病学会的心脏肿瘤学理事会的立场声明。
Eur J Heart Fail. 2020 Nov;22(11):1966-1983. doi: 10.1002/ejhf.2017. Epub 2020 Oct 20.
6
Cardiotoxicity of Anthracyclines.蒽环类药物的心脏毒性
Front Cardiovasc Med. 2020 Mar 18;7:26. doi: 10.3389/fcvm.2020.00026. eCollection 2020.
7
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry.抗癌治疗所致心脏毒性的分类、患病率及结局：CARDIOTOX注册研究
Eur Heart J. 2020 May 7;41(18):1720-1729. doi: 10.1093/eurheartj/ehaa006.
8
Cardio-Oncology Services: rationale, organization, and implementation.心血管肿瘤学服务：原理、组织和实施。
Eur Heart J. 2019 Jun 7;40(22):1756-1763. doi: 10.1093/eurheartj/ehy453.
9
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.蒽环类药物所致心脏毒性的预防：挑战与机遇。
J Am Coll Cardiol. 2014 Sep 2;64(9):938-45. doi: 10.1016/j.jacc.2014.06.1167.
10
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.超声心动图心肌应变成像技术用于早期检测癌症化疗期间和化疗后患者的心脏毒性：系统评价。
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68. doi: 10.1016/j.jacc.2014.01.073. Epub 2014 Apr 2.
Zotero 插件